لا يتم عرض هذه النتيجة على الضيوف.
تسجيل الدخول للوصول الكامل.

لا يتم عرض هذه النتيجة على الضيوف.
تسجيل الدخول للوصول الكامل.

المؤلفون: Ouellet D; GlaxoSmithKline, Research Triangle Park, NC, USA., Gibiansky E, Leonowens C, O'Hagan A, Haney P, Switzky J, Goodman VL

المصدر: Journal of clinical pharmacology [J Clin Pharmacol] 2014 Jun; Vol. 54 (6), pp. 696-706. Date of Electronic Publication: 2014 Jan 17.

نوع المنشور: Clinical Trial, Phase III; Journal Article; Multicenter Study

بيانات الدورية: Publisher: Wiley Country of Publication: England NLM ID: 0366372 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1552-4604 (Electronic) Linking ISSN: 00912700 NLM ISO Abbreviation: J Clin Pharmacol Subsets: MEDLINE

مواضيع طبية MeSH: Models, Biological*, Antineoplastic Agents/*pharmacokinetics , Imidazoles/*pharmacokinetics , Oximes/*pharmacokinetics , Protein Kinase Inhibitors/*pharmacokinetics , Proto-Oncogene Proteins B-raf/*antagonists & inhibitors, Adult ; Aged ; Aged, 80 and over ; Antineoplastic Agents/administration & dosage ; Antineoplastic Agents/blood ; Dose-Response Relationship, Drug ; Drug Administration Schedule ; Gelatin/chemistry ; Humans ; Hypromellose Derivatives/chemistry ; Imidazoles/administration & dosage ; Imidazoles/blood ; Male ; Middle Aged ; Oximes/administration & dosage ; Oximes/blood ; Protein Kinase Inhibitors/administration & dosage ; Protein Kinase Inhibitors/blood ; Young Adult

المؤلفون: Ascierto PA; Paolo A. Ascierto, Ester Simeone, Instituto Nazionale Tumori Fondazione 'G. Pascale,' Napoli, Italy; David Minor, California Pacific Center for Melanoma Research and Treatment, San Francisco; Antoni Ribas, Jonsson Comprehensive Cancer Center, University of California, Los Angeles; Omid Hamid, Experimental Therapeutics/Immunotherapy, The Angeles Clinic and Research Institute, Los Angeles, CA; Anne O'Hagan, Niki Arya, Mary Guckert, Anne-Marie Martin, Jolly Mazumdar, Vicki L. Goodman, GlaxoSmithKline Oncology, Collegeville; Ravi Amaravadi, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA; Kevin B. Kim, The University of Texas MD Anderson Cancer Center, Houston, TX; Celeste Lebbe, Assistance Publique-Hôpitaux de Paris, Hôpital Saint Louis, Paris, Université Paris Diderot, Paris; Jean-Jacques Grob, Aix-Marseille University, Assistance Publique-Hôpitaux de Marseille, Hôpital Timone, Marseille, France; Dirk Schadendorf, University Hospital Essen, Essen; Tabea Wilhelm, Uwe Trefzer, Charité-Universitätsmedizin, Berlin, Germany; Richard F. Kefford, Georgina V. Long, Westmead Hospital and Melanoma Institute Australia, University of Sydney, Sydney, Australia., Minor D, Ribas A, Lebbe C, O'Hagan A, Arya N, Guckert M, Schadendorf D, Kefford RF, Grob JJ, Hamid O, Amaravadi R, Simeone E, Wilhelm T, Kim KB, Long GV, Martin AM, Mazumdar J, Goodman VL, Trefzer U

المصدر: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2013 Sep 10; Vol. 31 (26), pp. 3205-11. Date of Electronic Publication: 2013 Aug 05.

نوع المنشور: Clinical Trial, Phase II; Journal Article; Multicenter Study

بيانات الدورية: Publisher: American Society of Clinical Oncology Country of Publication: United States NLM ID: 8309333 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1527-7755 (Electronic) Linking ISSN: 0732183X NLM ISO Abbreviation: J Clin Oncol Subsets: MEDLINE

مواضيع طبية MeSH: Brain Neoplasms/*drug therapy , Imidazoles/*therapeutic use , Melanoma/*drug therapy , Oximes/*therapeutic use , Proto-Oncogene Proteins B-raf/*antagonists & inhibitors, Adult ; Aged ; Aged, 80 and over ; Brain Neoplasms/mortality ; Brain Neoplasms/secondary ; Female ; Follow-Up Studies ; Humans ; International Agencies ; Male ; Melanoma/mortality ; Melanoma/pathology ; Middle Aged ; Mutation/genetics ; Prognosis ; Proto-Oncogene Proteins B-raf/genetics ; Survival Rate ; Young Adult

المؤلفون: Xu CF; Department of Genetics, GlaxoSmithKline Research and Development, Stevenage, UK., Xue Z; Department of Genetics, GlaxoSmithKline Research and Development, Research Triangle Park, Philadelphia., Bing N; Department of Genetics, GlaxoSmithKline Research and Development, Research Triangle Park, Philadelphia., King KS; Department of Genetics, GlaxoSmithKline Research and Development, Research Triangle Park, Philadelphia., McCann LA; Department of Clinical Statistics, GlaxoSmithKline Research and Development, Philadelphia, USA., de Souza PL; Department of Medical Oncology, University of Western Sydney School of Medicine, Sydney, Australia., Goodman VL; Department of Oncology, GlaxoSmithKline Research and Development, Research Triangle Park, Philadelphia, United States., Spraggs CF; Department of Genetics, GlaxoSmithKline Research and Development, Stevenage, UK., Mooser VE; Department of Genetics, GlaxoSmithKline Research and Development, Research Triangle Park, Philadelphia., Pandite LN; Department of Oncology, GlaxoSmithKline Research and Development, Research Triangle Park, Philadelphia, United States.

المصدر: Annals of oncology : official journal of the European Society for Medical Oncology [Ann Oncol] 2012 Sep; Vol. 23 (9), pp. 2470-2471.

نوع المنشور: Letter; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Elsevier Country of Publication: England NLM ID: 9007735 Publication Model: Print Cited Medium: Internet ISSN: 1569-8041 (Electronic) Linking ISSN: 09237534 NLM ISO Abbreviation: Ann Oncol Subsets: MEDLINE

مواضيع طبية MeSH: Alanine Transaminase/*blood , Anticholesteremic Agents/*pharmacology , Antineoplastic Agents/*pharmacology , Neoplasms/*blood , Pyrimidines/*pharmacology , Simvastatin/*pharmacology , Sulfonamides/*pharmacology, ATP Binding Cassette Transporter, Subfamily G, Member 2 ; ATP-Binding Cassette Transporters/genetics ; Anticholesteremic Agents/adverse effects ; Anticholesteremic Agents/therapeutic use ; Antineoplastic Agents/adverse effects ; Antineoplastic Agents/therapeutic use ; Chemical and Drug Induced Liver Injury/epidemiology ; Chemical and Drug Induced Liver Injury/genetics ; Clinical Trials as Topic ; Drug Interactions ; Humans ; Hypercholesterolemia/blood ; Hypercholesterolemia/drug therapy ; Incidence ; Indazoles ; Neoplasm Proteins/genetics ; Neoplasms/drug therapy ; Polymorphism, Single Nucleotide ; Pyrimidines/adverse effects ; Pyrimidines/therapeutic use ; Reference Values ; Simvastatin/adverse effects ; Simvastatin/therapeutic use ; Sulfonamides/adverse effects ; Sulfonamides/therapeutic use

المؤلفون: Xu CF; GlaxoSmithKline Research and Development, Genetics Division, Stevenage, UK. chun-fang.2.xu@gsk.com, Reck BH, Goodman VL, Xue Z, Huang L, Barnes MR, Koshy B, Spraggs CF, Mooser VE, Cardon LR, Pandite LN

المصدر: Journal of hepatology [J Hepatol] 2011 Jun; Vol. 54 (6), pp. 1237-43. Date of Electronic Publication: 2011 Feb 12.

نوع المنشور: Clinical Trial, Phase II; Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Elsevier Country of Publication: Netherlands NLM ID: 8503886 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1600-0641 (Electronic) Linking ISSN: 01688278 NLM ISO Abbreviation: J Hepatol Subsets: MEDLINE

مواضيع طبية MeSH: Alanine Transaminase/*blood , Antineoplastic Agents/*adverse effects , Carcinoma, Renal Cell/*drug therapy , Carcinoma, Renal Cell/*enzymology , Histocompatibility Antigens Class I/*genetics , Kidney Neoplasms/*drug therapy , Kidney Neoplasms/*enzymology , Membrane Proteins/*genetics , Pyrimidines/*adverse effects , Sulfonamides/*adverse effects, Aged ; Angiogenesis Inhibitors/adverse effects ; Carcinoma, Renal Cell/genetics ; Female ; Genes, MHC Class I ; Genes, MHC Class II ; Genetic Markers ; Hemochromatosis Protein ; Humans ; Indazoles ; Kidney Neoplasms/genetics ; Male ; Middle Aged ; Pharmacogenetics ; Polymorphism, Single Nucleotide

المؤلفون: Goodman VL; Division of Drug Oncology Products, U.S. Food and Drug Administration, Sliver Spring, Maryland 20903, USA. vicki.goodman@fda.hhs.gov, Rock EP, Dagher R, Ramchandani RP, Abraham S, Gobburu JV, Booth BP, Verbois SL, Morse DE, Liang CY, Chidambaram N, Jiang JX, Tang S, Mahjoob K, Justice R, Pazdur R

المصدر: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2007 Mar 01; Vol. 13 (5), pp. 1367-73.

نوع المنشور: Journal Article; Review

بيانات الدورية: Publisher: The Association Country of Publication: United States NLM ID: 9502500 Publication Model: Print Cited Medium: Print ISSN: 1078-0432 (Print) Linking ISSN: 10780432 NLM ISO Abbreviation: Clin Cancer Res Subsets: MEDLINE

مواضيع طبية MeSH: Antineoplastic Agents/*therapeutic use , Carcinoma, Renal Cell/*drug therapy , Gastrointestinal Stromal Tumors/*drug therapy , Indoles/*therapeutic use , Kidney Neoplasms/*drug therapy , Piperazines/*therapeutic use , Pyrimidines/*therapeutic use , Pyrroles/*therapeutic use, Benzamides ; Drug Approval ; Drug Resistance, Neoplasm ; Humans ; Imatinib Mesylate ; Randomized Controlled Trials as Topic ; Sunitinib ; United States ; United States Food and Drug Administration